Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Seres

This Electric SUV From Huawei Projects a 100-Inch Movie Screen With Its Headlights

Huawei’s latest EV features adaptive LED headlights that can go from projecting important driver information to a movie on a 100-inch display.

FDA approves first-ever pill made from healthy gut bacteria found in human waste

FDA approves first-ever pill made from healthy gut bacteria found in human waste

The pill paves way for an easier way of performing so-called faecal transplants

The Independent UK

First pill for fecal transplant wins FDA approval

First pill for fecal transplant wins FDA approval

U.S. health officials have approved the first pill that uses healthy bacteria from human waste to fight dangerous gut infections — an easier way of performing so-called fecal transplants

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

XPeng Cuts Prices In China By Up To 13 Percent, EV Price War Is On

XPeng's move to cut prices follows a similar decision from Aito, the premium brand backed by Huawei and Seres, which slashed M5 and M7 prices by up to $4,500.

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Huawei-Backed Seres' Aito Brand To Use CATL Qilin Batteries

CATL announced a strategic cooperation agreement with Seres, which intends to use the Qilin battery system in its new Aito premium EV brand, backed by Huawei.

Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

Seres Therapeutics Inc (NASDAQ:MCRB) announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI). The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated. The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program. In ECOSPOR…

inkl

Read news from The Economist, FT, and more,
with one subscription

EV Primus optimistic on outlook for electric vehicles

EV Primus optimistic on outlook for electric vehicles

EV Primus Co, the distributor of China's second largest automaker DFSK (Dongfeng), expects a bustling electric vehicle (EV) industry in Thailand as more Chinese car companies enter the market following the launch of the government's EV incentive package.

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis

Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis

In its SEC filing, Seres Therapeutics Inc (NASDAQ: MCRB) disclosed it would not move forward with the planned SER-301 Phase 1b second study cohort. In its Q4 earnings release, Seres said that SER-301 was safe to proceed to the placebo-controlled second cohort in a Phase Ib trial even though outcome data from the…

Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection

Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection

Seres Therapeutics Inc (NASDAQ: MCRB) has

Organisations

European Commission

US Food and Drug Administration

Ionis Pharmaceuticals

Bicycle rapeutics

Pacira Biosciences

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Ulcerative Colitis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

265,440 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play